METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
L.L. Siu,
Drew Rasco,
S. P. Vinay,
P. Martin Romano,
Jessica Menis,
Frans L. Opdam,
Kimberley M. Heinhuis,
Jacqueline L. Egger,
Shelby Gorman,
Ridhi Parasrampuria,
Annals of Oncology · 2019 · 133 citations · 0 references